Exiger Report Highlights U.S. Dependence on China for Pharmaceuticals

Exiger has published a report revealing critical vulnerabilities in the U.S. healthcare supply chain, particularly its reliance on China for pharmaceuticals. The report, titled "A Bitter Pill: America's Dangerous Dependence on China-Made Pharmaceuticals," was announced in a press release and highlights that 90% of U.S. antibiotic active pharmaceutical ingredients (APIs) are sourced from China.

Exiger's investigation, utilizing its AI-powered supply chain platform, assessed over 2,300 companies and 1,376 APIs. The findings indicate severe quality control issues, unethical sourcing practices, and a significant dependency on foreign manufacturers. The report also points out that more than 30% of new import alerts were for Chinese sites, underscoring recurring manufacturing problems.

The report emphasizes the need for urgent measures to protect U.S. healthcare, such as increasing domestic production and enhancing supply chain transparency. Exiger's CEO, Brandon Daniels, noted the implications of these dependencies amid geopolitical tensions, stressing the importance of strategic stockpiling and diversification to safeguard American health and national security.